Former FDA Chief Counsel Thomas Scarlett
Joins Washington, D.C. food and drug law firm Hyman, Phelps and McNamara as a partner. Scarlett was with the agency from 1973-1979. He rejoined FDA from private practice in 1981 as chief counsel. . . .
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.